JCB logo
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 6 May 2002. doi:10.1083/jcb.200201049
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinz, B.
Right arrow Articles by Chaponnier, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinz, B.
Right arrow Articles by Chaponnier, C.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0021-9525/2002/5/657 $5.00
The Journal of Cell Biology, Volume 157, Number 4, May 13, 2002 657-663


Article

The NH2-terminal peptide of {alpha}–smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo

Boris Hinz, Giulio Gabbiani and Christine Chaponnier

Department of Pathology, Centre Médical Universitaire, University of Geneva, 1211 Geneva 4, Switzerland

Address correspondence to Giulio Gabbiani, Dept. of Pathology, CMU, University of Geneva, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland. Tel.: 41-22-702-5742. Fax: 41-22-702-5746. E-mail: Giulio.Gabbiani{at}medecine.unige.ch

Myofibroblasts are specialized fibroblasts responsible for granulation tissue contraction and the soft tissue retractions occurring during fibrocontractive diseases. The marker of fibroblast-myofibroblast modulation is the neo expression of {alpha}–smooth muscle actin ({alpha}-SMA), the actin isoform typical of vascular smooth muscle cells that has been suggested to play an important role in myofibroblast force generation. Actin isoforms differ slightly in their NH2-terminal sequences; these conserved differences suggest different functions. When the NH2-terminal sequence of {alpha}-SMA Ac-EEED is delivered to cultured myofibroblast in the form of a fusion peptide (FP) with a cell penetrating sequence, it inhibits their contractile activity; moreover, upon topical administration in vivo it inhibits the contraction of rat wound granulation tissue. The NH2-terminal peptide of {alpha}–skeletal actin has no effect on myofibroblasts, whereas the NH2-terminal peptide of ß–cytoplasmic actin abolishes the immunofluorescence staining for this isoform without influencing {alpha}-SMA distribution and cell contraction. The FPs represent a new tool to better understand the specific functions of actin isoforms. Our findings support the crucial role of {alpha}-SMA in wound contraction. The {alpha}-SMA–FP will be useful for the understanding of the mechanisms of connective tissue remodeling; moreover, it furnishes the basis for a cytoskeleton-dependent preventive and/or therapeutic strategy for fibrocontractive pathological situations.

Key Words: actin isoforms; wound healing; granulation tissue; TGFß; fibrosis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents